This discovery points to a novel avenue for immunotherapy, in combination with other anticancer treatments, which could be harnessed to target CD80 expression levels and ultimately eradicate FLT3-ITD AML cells in future. This evidence concerns the gene FLT3 and acute myeloid leukemia.